Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/Simvastatin plus Fenofibrate vs Fenofibrate in Mixed Hyperlipidemia
2004-003807-19Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2004
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in combined dyslipidaemia comparing Vytorin + fenofibrate, fenofibrate monotherapy and Vytorin monotherapy (3 arms). Primary endpoint: Percent change in LDL-C from baseline to 12 weeks. Started Oct 2004; status: completed.
02
Drugs
Vytorinfenofibrate
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on 2004-003807-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003807-19.